[转载]ADNI3 Introduction

已有 1166 次阅读 2019-3-14 14:56 |个人分类:dataset|系统分类:科研笔记| ADNI3

ADNI3 begin in 2016. Between 1070-2000 participants will be enrolled: approximately 700-800 rollover participants from ADNI2 and 370-1200 newly enrolled subjects.  Clinical, cognitive, imaging, biomarker and genetic characteristics will be assessed across three cohorts: Cognitively normal, MCI and mild AD dementia.


In addition to all the biomarkers used in ADNI 2, ADNI 3 has the following changes and additions:

  1. ADNI 3 includes longitudinal tau PET scans with AV 1451 provided by AVID. The study also includes the development of tau PET as a surrogate outcome measure for AD clinical trials.

  2. For new ADNI 3 subjects, we will be using Florbetaben provided by Piramal for amyloid PET.

  3. CSF amyloid and tau will be measured using a new immunoassay platform provided by Roche to determine how tau tangles are related to amyloid levels and to cognition.

  4. MRI techniques from the Human Connectome Project will be used to map the effects of AD on brain connectivity. Protocols will be updated including 3D ASL perfusion imaging and Connectome sequences for appropriate scanners.

  5. Use of high-powered MRI to detect very early structural brain changes in AD.

  6. For the clinical battery, the Financial Capacity Instrument has been added and subjects will take Cogstate computerized testing in-clinic and at home and subjects will be invited to join the Brain Health Registry for at-home assessment. The Brain Health Registry also supports recruitment activities.

  7. Use of Systems Biology approaches to understand AD genetics and its relationship to AD biology.

  8. Development of models to select patients for AD clinical trials using Precision medicine


The figure is from

上一篇:ADNI Introduction--Experimental conclusion


该博文允许注册用户评论 请点击登录 评论 (0 个评论)


Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2022-5-21 14:45

Powered by

Copyright © 2007- 中国科学报社